I-Mab Announces Upcoming Participation at April Conferences
03/31/2021 - 08:00 AM
SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologic, today announced its participation in the following conferences in April. Details of the conferences and management presentation are as follows:
20th Annual Needham Healthcare Conference (Virtual) Presentation: Tuesday, April 13, 2021 at 8:45 a.m. ET Presenter: Dr. Jingwu Zang, Founder, Chairman and Director
Webcast link: https://wsw.com/webcast/needham107/imab/2212474 . The webcast will also be available under “Event Calendar” on IMAB’s IR website at http://ir.i-mabbiopharma.com/ .
One-on-one meetings: April 12-15, 2021 Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior Director Investor Relations
For more information, please contact your Needham representative.
2021 Haitong Securities Spring Listed Companies Conference Presentation: Thursday, April 15, 2021 at 11:00 a.m. Beijing Time Presenter: Ms. Leah Liu, Senior Director Investor Relations Location: Hangzhou
One-on-one and small group meetings: April 14-16, 2021 Management participant: Ms. Leah Liu, Senior Director Investor Relations
For more information, please contact your Haitong representative.
UBS Healthcare Summit 2021 (Virtual) Management participants: Dr. Jingwu Zang, Founder, Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior Director Investor Relations
One-on-one and small group meetings: April 27-29, 2021
For more information, please contact your UBS representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company's mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab's globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company's unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou and Hong Kong in China, and Maryland and San Diego in the United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter and WeChat .
For more information, please contact:
I-Mab
Jielun Zhu, Chief Financial Officer E-mail: jielun.zhu@i-mabbiopharma.com Office line: +86 21 6057 8000
Gigi Feng, Chief Communications Officer E-mail: gigi.feng@i-mabbiopharma.com Office line: +86 21 6057 5785
Investor Inquiries:
The Piacente Group, Inc. Emilie Wu E-mail: emilie@thepiacentegroup.com Office line: +86 21 6039 8363
IMAB Rankings
#5074 Ranked by Stock Gains
IMAB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About IMAB
i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm